This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (24)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

James E. Dalen, MD

Arch Intern Med. 1991;151(6):1066-1069.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

In 1989, the Second American College of Chest Physicians (ACCP) Conference on Antithrombotic Therapy¹ recommended that aspirin, 325 mg/d, should be considered for all individuals with evidence of coronary artery disease and in those with risk factors for coronary artery disease. Aspirin, 1 g/d, was also recommended by the ACCP Panel² for patients with transient ischemic attacks (TIAs), or a history of stroke. These recommendations, which apply to millions of Americans, were based on the results of a long series of reports and clinical trials dating back to 1948.

The recommendation that all individuals with evidence of coronary artery disease should take aspirin daily is based on the results of aspirin treatment in survivors of acute myocardial infarction,^3-9 patients with unstable angina,^10-12 patients with acute myocardial infarction,¹³ patients surviving coronary artery bypass grafting,¹⁴ and patients undergoing percutaneous transluminal coronary angioplasty.^15,16 The recommendation for . . . [Full Text PDF of this Article]

Author Affiliations
Editor

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?